Multiple Myeloma

Celgene advances after analysts say Revlimid data positive
Celgene advances after analysts say Revlimid data positive
The Fly on the Wall
Revlimid
Celgene
Multiple Myeloma
Flag link:
Novartis bone marrow cancer drug meets goal in late-stage study
Novartis bone marrow cancer drug meets goal in late-stage study
Yahoo/AP
Novartis
LBH589
Multiple Myeloma
Flag link:
Celgene's Revlimid Faces a Tough Sell
Celgene's Revlimid Faces a Tough Sell
Motley Fool
Celgene
Revlimid
JNJ
Multiple Myeloma
Flag link:
Has Myeloma Met Its Match in Amgen's Kyprolis?
Has Myeloma Met Its Match in Amgen's Kyprolis?
Motley Fool
Multiple Myeloma
Amgen
Kyprolis
Celgene
Flag link:
Celgene's Revlimid Makes Stronger Case for European Front-Line Approval
Celgene's Revlimid Makes Stronger Case for European Front-Line Approval
TheStreet.com
Celgene
Revlimid
Europe
Multiple Myeloma
Flag link:
J&J's Velcade gets stiff-armed at NICE as first-line myeloma treatment
J&J's Velcade gets stiff-armed at NICE as first-line myeloma treatment
Fierce Pharma
JNJ
Velcade
Multiple Myeloma
Flag link:
Array Biopharma Outlines Path To Market For New Myeloma Drug
Array Biopharma Outlines Path To Market For New Myeloma Drug
Forbes
Multiple Myeloma
Array Biopharma
ARRY-520
Kyprolis
Flag link:
Celgene's New Multiple Myeloma Drug Is Beating Amgen
Celgene's New Multiple Myeloma Drug Is Beating Amgen
TheStreet.com
Celgene
Multiple Myeloma
Amgen
Kyprolis
Pomalyst
Flag link:
Celgene says phase III study of pomalidomide combo met primary endpoint
Celgene says phase III study of pomalidomide combo met primary endpoint
Yahoo/Fly on the Wall
Celgene
pomalidomide
Multiple Myeloma
Flag link:
Celgene's Multiple Myeloma Powerhouse
Celgene's Multiple Myeloma Powerhouse
Motley Fool
Multiple Myeloma
Celgene
Thalomid
Revlimid
Pomalyst
Flag link:
Celgene spends $100M for option to buy myeloma drug developer Acetylon
Celgene spends $100M for option to buy myeloma drug developer Acetylon
Fierce Biotech
Celgene
Multiple Myeloma
M&A
Acetylon
Flag link:
Celgene's Revlimid improves survival in blood cancer patients
Celgene's Revlimid improves survival in blood cancer patients
Reuters
Celgene
Revlimid
Multiple Myeloma
Flag link:
Coronado Biosciences Reuniting Old Friends
Coronado Biosciences Reuniting Old Friends
Seeking Alpha
Coronado Biosciences
CNDO-201
CNDO-109
Crohn's Disease
Multiple Myeloma
acute myeloid leukemia
Flag link:
MorphoSys Rises on $818 Million Drug Alliance
MorphoSys Rises on $818 Million Drug Alliance
Bloomberg
MorphoSys
MOR202
Celgene
Multiple Myeloma
Flag link:
Johnson & Johnson's Potential Blockbuster For Multiple Myeloma And Its Competitors
Johnson & Johnson's Potential Blockbuster For Multiple Myeloma And Its Competitors
Seeking Alpha
JNJ
Multiple Myeloma
daratumumab
Genmab
Flag link:
Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting
Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting
Yahoo/MarketWire
Threshold Pharmaceuticals
TH-302
Multiple Myeloma
gastrointestinal stromal tumors
renal cell carcinoma
kidney cancer
Flag link:
Genmab Rises After FDA Grants Breakthrough Status to Cancer Drug
Genmab Rises After FDA Grants Breakthrough Status to Cancer Drug
Bloomberg
Genmab
FDA
JNJ
daratumumab
Multiple Myeloma
Flag link:
Celgene's Star Drug Revlimid And Its Competitors
Celgene's Star Drug Revlimid And Its Competitors
Seeking Alpha
Celgene
Revlimid
Multiple Myeloma
JNJ
Velcade
AbbVie
Bristol-Myers Squibb
elotuzumab
Flag link:
Genmab Rises as Nordea Says Bet on Cancer Drug: Copenhagen Mover
Genmab Rises as Nordea Says Bet on Cancer Drug: Copenhagen Mover
Bloomberg
Genmab
JNJ
daratumumab
Multiple Myeloma
Flag link:
Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation
Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation
Yahoo
Aeterna Zentaris
Multiple Myeloma
perifosine
Flag link:

Pages